Johnson & Johnson (JNJ) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / October 20, 2026 /Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("Johnson & Johnson" or "the Company") (NYSE:JNJ). Investors who purchased Johnson & Johnson securities are encouraged to obtain additional information and assist the investigation by visiting the firm 's site: bgandg.com/cases/johnson-johnson-jnj-investigation.
Johnson & Johnson Investigation Details
On October 13, 2026, Johnson & Johnson announced its third-quarter 2026 financial results, reporting that sales in its MedTech division increased just 2.5% to approximately $8.64 billion, falling short of analysts ' expectations of $8.74 billion. The Company also reported a 95.9% year-over-year decline in net earnings to $210 million, primarily reflecting special charges related to its proposed talc litigation resolution and acquisition-related expenses. Despite raising its full-year guidance, the Company 's results raised concerns regarding continued weakness in its medical devices business, including pricing pressures in China and budget constraints in Europe. Following this news, Johnson & Johnson 's stock price declined approximately 5.7% on October 13, 2026.
What 's Next for Johnson & Johnson Investors?
If you are aware of any facts relating to this investigation or purchased Johnson & Johnson securities, you can assist this investigation by visiting the firm 's site: bgandg.com/cases/johnson-johnson-jnj-investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Johnson & Johnson Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys ' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Johnson & Johnson Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE:Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.
